Skip to NavigationSkip to content

prostate cancer

Bayer's Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men who are at high risk of developing metastatic disease.

Phase 3 data supporting the approval showed that Bayer’s drug, in combination with androgen deprivation therapy (ADT), improved metastasis-free survival by a median of 40.4 months compared to just 18.4 months with placebo plus ADT, meeting the trial’s primary goal.

Prostate Cancer becomes most commonly diagnosed cancer in England

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest figures show.

In 2018, there were nearly 8,000 more cases than in 2017. Overall there were 316,680 cancers diagnosed in 2018, with prostate being the most common type with 49,029 cases, with breast cancer close behind with 47,476 cases.

NHS Scotland recommends Janssen's Zytiga combo for newly diagnosed prostate cancer

Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the NHS in Scotland will now be able to access the drug in combination with prednisone or prednisolone plus androgen deprivation therapy (ADT) for the treatment of newly diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC).

The most common cancer in UK men, there are around 47,000 new cases of prostate cancer in the country every year.

Largest drop ever in US cancer mortality rates, new study shows

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline recorded by the American Cancer Society (ACS).

The study was published this week in A Cancer Journal for Clinicians. It shows that the overall cancer death rate rose in the US until 1991, then fell continuously through to 2017. This resulting in a decline of 29% in cancer mortality rates which translated roughly to 2.9 million less deaths.

AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as well as African, countries to Juvisé Pharmaceuticals.

These medicines are used primarily to treat breast and prostate cancers. AstraZeneca already divested the rights to both Arimidex and Casodex in the US in 2017.

Last year, Arimidex recorded a record $37 million in sales while Casodex made $24 million, in the regions where AstraZeneca has sold the right to Juvisé.

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer.

The approval allows the treatment to be used on patients with metastatic hormone-sensitive prostate cancer, which is a form of the disease that spreads to other parts of the body. 400,000 men live with this disease in the US.

The drug is the first oral treatment approved by the FDA to be used in treating three different types of advanced prostate cancer.

Prostate Cancer ‘super responders’ could live for two more years on Keytruda

Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for another two years or more.

A major clinical trial showed that a small proportion of men were ‘super responders’ and were alive and well even after the trial had ended, despite having had a very poor prognosis before treatment.

Sanofi's Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new data showing that its microtubule inhibitor Jevtana (cabazitaxel) met its primary endpoint in the treatment of metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone.

It was shown that the combo more than doubled radiographic progression free survival (rPFS) to a median of eight months, compared to 3.7 months with abiraterone or enzalutamide, clearing the primary endpoint of the study.

FDA expands Janssen's Erleada label to cover metastatic castration-sensitive prostate cancer

Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

The therapy was evaluated under Priority Review Designation through the US regulator’s Real-Time Oncology Review programme. It is estimated that around 40,000 new diagnoses of mCSPC are made in the US each year.

AstraZeneca's Lynparza meets primary endpoint in Phase 3 prostate cancer trial

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic prostate cancer.

The drug met its primary endpoint in the Phase 3 PROfound  trial of men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches